NCT03629418 Targeted Blood-pressure Management and Acute Kidney Injury After Coronary Artery Bypass Surgery
| NCT ID | NCT03629418 |
| Status | Recruiting |
| Phase | — |
| Sponsor | Peking University First Hospital |
| Condition | Coronary Artery Bypass, Off-Pump |
| Study Type | INTERVENTIONAL |
| Enrollment | 612 participants |
| Start Date | 2018-08-14 |
| Primary Completion | 2025-12 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
You will actively receive the study intervention — which may be a drug, biologic, device, or procedure.
This trial targets 612 participants in total. It began in 2018-08-14 with a primary completion date of 2025-12.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
Acute renal injury (AKI) is a common complication after cardiac surgery and is associated with worse outcomes. It is now realized that intraoperative hypotension is an important risk factor for the development of AKI. In a recent randomized controlled trial of patients undergoing major noncardiac surgery, intraoperative individualized blood-pressure management reduced the incidence of postoperative organ dysfunction. The investigators hypothesize that, for patients undergoing off-pump CABG, targeted blood-pressure management during surgery may also reduce the incidence of postoperative AKI.
Eligibility Criteria
Inclusion Criteria: * Age ≥ 50 years; * Scheduled to undergo off-pump CABG surgery. Exclusion Criteria: * Refuse to participate; * Untreated or uncontrolled severe hypertension (systolic blood pressure ≥180 mmHg or diastolic blood pressure ≥110 mmHg); * Chronic kidney disease with a glomerular filtration rate \< 30 ml/min/1.73 m2 or end-stage renal disease requiring renal-replacement therapy; * Inability to communicate during the preoperative period because of coma, profound dementia, language barrier, or end-stage disease; * Requirement of vasopressors/inotropics to maintain blood pressure before surgery; * Second or emergency surgery; * Expected survival of less than 24 hours.
Contact & Investigator
Dong-Xin Wang, MD, PhD
PRINCIPAL INVESTIGATOR
Peking University First Hospital
Frequently Asked Questions
Who can join the NCT03629418 clinical trial?
This trial is open to participants of all sexes, aged 50 Years or older, studying Coronary Artery Bypass, Off-Pump. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT03629418 currently recruiting?
Yes, NCT03629418 is actively recruiting participants. Contact the research team at wangdongxin@hotmail.com for enrollment information.
Where is the NCT03629418 trial being conducted?
This trial is being conducted at Beijing, China.
Who is sponsoring the NCT03629418 clinical trial?
NCT03629418 is sponsored by Peking University First Hospital. The principal investigator is Dong-Xin Wang, MD, PhD at Peking University First Hospital. The trial plans to enroll 612 participants.